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Abstract
Purpose The aim of this study was to evaluate AZD2995
side by side with AZD2184 as novel PET radioligands for
imaging of amyloid-β in Alzheimer’s disease (AD).
Methods In vitro binding of tritium-labelled AZD2995 and
AZD2184 was studied and compared with that of the estab-
lished amyloid-β PET radioligand PIB. Subsequently, a first-in-
human in vivo PETstudy was performed using [11C]AZD2995
and [11C]AZD2184 in three healthy control subjects and seven
AD patients.
Results AZD2995, AZD2184 and PIB were found to share
the same binding site to amyloid-β. [3H]AZD2995 had the
highest signal-to-background ratio in brain tissue from
patients with AD as well as in transgenic mice. However,
[11C]AZD2184 had superior imaging properties in PET, as
shown by larger effect sizes comparing binding potential
values in cortical regions of AD patients and healthy controls.
Nevertheless, probably due to a lower amount of nonspecific
binding, the group separation of the distribution volume ratio
values of [11C]AZD2995 was greater in areas with lower
amyloid-β load, e.g. the hippocampus.
Conclusion Both AZD2995 and AZD2184 detect amyloid-
β with high affinity and specificity and also display a lower
degree of nonspecific binding than that reported for
PIB. Overall [11C]AZD2184 seems to be an amyloid-β
radioligand with higher uptake and better group separa-
tion when compared to [11C]AZD2995. However, the
very low nonspecific binding of [11C]AZD2995 makes
this radioligand potentially interesting as a tool to study
minute levels of amyloid-β. This sensitivity may be
important in investigating, for example, early prodromal
stages of AD or in the longitudinal study of a disease
modifying therapy.
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Introduction
Deposition of amyloid plaques containing Aβ fibrils in the
brain is a key biomarker for the post mortem diagnosis of
Alzheimer’s disease (AD) [1, 2]. Using PET it is possible to
study amyloid-β pathology in vivo using radioligands that
specifically target amyloid-β. The first and so far most
widely applied radioligand is [11C]PIB (2-[4′-(methylami-
no)phenyl]-6-hydroxybenzothiazole), which binds specifi-
cally to amyloid-β plaques [3]. PET imaging with [11C]
PIB has been demonstrated to be able to distinguish between
AD patients and healthy controls with high specificity and
sensitivity [4, 5]. However, the observation that [11C]PIB
displays relatively high nonspecific binding in nontarget
areas may pose a limitation to its ability to measure discrete
changes in amyloid-β load caused by disease progression or
drug therapy that lowers amyloid-β. PET imaging studies
using [11C]PIB have also exposed limitations when it is used
in mouse models of amyloidosis possibly due to a lower
number of binding sites than in AD patients [6, 7].
[18F]FDDNP (2-(1-{6-[18]fluoroethyl}(methyl)amino)-
2-naphthyl)ethylidene)malonononitrile) binds both
amyloid-β plaques and neurofibrillary tangles, and it has
therefore been suggested that it could be sensitive to
pathological changes early in the disease progress [8].
However, when compared to other amyloid radioligands,
[18F]FDDNP has a ninefold lower specific binding sig-
nal in AD patients, which might explain why recent
longitudinal studies have shown different results [9].
One study has shown a relationship between [18F]
FDDNP and memory decline [10] while another study
using [18F]FDDNP failed to reveal pathological progres-
sion [11]. Thus, a PET radioligand with lower nonspe-
cific and higher specific binding to amyloid-β would
provide an improvement in in vivo PET imaging in
human subjects and in various animal models of AD.
The aim of the present study was to develop a 11C-
labelled ligand with minimal nonspecific binding for re-
search and multitracer studies. The overall hypothesis was
that lower lipophilicity (logD) than that of previously de-
veloped radioligands would translate into lower nonspecific
binding. Data have previously been presented for [11C]
AZD2184 [12–14] and [18F]AZD4694 [15, 16]. In parallel
a third compound, AZD2995 with an even lower logD (1.3)
than that of AZD2184 (1.8) and PIB (2.8) [17] has been
developed.
The first aim of this study was to examine the binding
properties of AZD2995 in a preclinical setting and compare
these properties with those of AZD2184 and PIB. In addi-
tion, binding was examined in an initial PET study of [11C]
AZD2995 in control subjects and AD patients. The previ-
ously developed radioligand [11C]AZD2184 was used in




Transgenic mice (approximately 18 months old) were
used for in vitro binding assays and to examine label-
ling after in vivo administration of the respective radio-
ligand as described below. Double transgenic APP/PS1
mice were generated in-house via heterozygous breeding
of mice expressing the 695 isoform of the human AD
amyloid precursor protein containing the double muta-
tion Lys670-Asn,Met671-Leu (Swedish mutation) [18]
under transcriptional control of the hamster prion pro-
moter and of mice expressing mutated human presenilin
gene Met146-Leu under transcriptional control of the rat
platelet-derived growth factor-b promoter [19]. All ani-
mals were housed at the AstraZeneca animal facility
(AstraZeneca R&D, Södertälje, Sweden). Housing was
humidity- and temperature-controlled. Food and water
were provided ad libitum and the light/dark cycle was
12/12 h. All animal studies were approved by the
Stockholm Animal Research Ethics Committee, and all
experiments were performed in accordance with the
guidelines of the Swedish Animal Welfare Agency.
Human tissue
Cortical samples from AD patients were acquired from the
Netherlands Brain Bank and used to examine radioligand
binding to amyloid-β plaques. The tissue samples were used
in accordance with the Swedish Biobank Law and AstraZe-
neca guidelines to protect the integrity of the donor. Cortical
samples were from the brain of a female 83-year-old ApoE
4/4 carrier with diagnosed AD (from the gyrus inferior
frontalis).
Radioligand binding and competition assays
The saturation binding assays on synthetic human Aβ(1-40)
fibrils to determine the equilibrium dissociation constant
(Kd) and density of binding sites (Bmax) of [
3H]AZD2995
have been previously described [15]. To further characterize
the binding mode of AZD2995, competition binding studies
with unlabelled compound were conducted using either
Aβ(1-40) or Aβ(1-42) fibrils at different concentrations of
[3H]PIB (0.5–35 nM) as described previously [15]. All
measurements were performed in duplicate and repeated
three to six times. The Kd, Bmax and pIC50 were determined
from the experimental results by nonlinear regression anal-
ysis using GraphPad Prism (version 4.03; GraphPad Soft-
ware, San Diego, CA).
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Dissociation assay
Dissociation studies were used to determine the dissociation
rates and reversibility of [3H]AZD2995 binding to synthetic
Aβ(1-40) fibrils. For this purpose, 400 μl of 0.25 μM Aβ
(1-40) in phosphate buffer (pH 7.5) and 50 μl of 10 nM [3H]
AZD2995 were dissolved in assay buffer with 0.1 % BSA
and incubated for 2.5 h in ABgene Mark II 96 deep-well
plates. The displacement was initiated by addition of 10 μl
of 460 μM AZD2995 in DMSO at different time points
(0–90 min) prior to filtration. Additions of 10 μl DMSO
were done to control wells at the time points 90, 60 and
30 min prior to filtration to control for the dissociation effect
of the DMSO. The displacement was terminated by filtra-
tion through a Whatman GF/B glass microfibre filter (What-
man International, Maidstone, UK) prewetted with 0.5 %
BSA in wash buffer, with a Brandel M-48TI cell harvester
(Brandel, Gaithersburg, MD) and washed rapidly three
times with 2 ml of ice-cold wash buffer (10 mM HEPES,
pH 7.4, containing 500 mM NaCl). The filters were equil-
ibrated for 2 h with 4 ml of Ultima Gold scintillation fluid
(PerkinElmer, Waltham, MA) and counted in a Packard
Tricarb 2900TR liquid scintillation analyser (PerkinElmer).
Results were corrected for nonspecific, nondisplaceable
binding, defined as the number of counts from wells
without Aβ(1-40) fibrils using only assay buffer. All
measurements were performed in duplicate and each
experiment was repeated four times.
In vitro autoradiography on brain sections from APP/PS1
mice and AD patient
In vitro autoradiography was performed as described previ-
ously [13, 15]. Briefly, 10 μm thick cryo-cut tissue sections
from APP/PS1 transgenic mice or human post mortem AD
brain were incubated in 50 mM Tris buffer (pH 7.4) at room
temperature followed by 30 min incubation with [3H]PIB,
[3H]AZD2184 or [3H]AZD2995 in Tris buffer.
To determine the signal-to-noise ratio, regions of
interest (ROIs) in the grey and white matter were out-
lined with Multi Gauge V3.0 software (Fuji) and the
optical densities measured as digital light units per
square millimetre. The signal-to-noise ratio was obtained
by subtracting the nonspecific binding (subcortical white
matter region) from the total binding (grey matter
regions) and then dividing by the nonspecific binding
(i.e. specific binding/nonspecific binding).
High-resolution amyloid-β autoradiography
Emulsion-dipped [3H]AZD2995 labelled tissue sections for
microscopic analysis were prepared as described previously
[13]. In brief, 10-μm slide-mounted cryo-cut tissue sections
were labelled with 1 nM of [3H]AZD2995 and dipped in NTB-
2 liquid emulsion (Kodak, Rochester, NY) at 42 °C. The slides
were air-dried and exposed for 1–2 weeks in the dark, devel-
oped and counterstained with haematoxylin (Histolab,
Göteborg, Sweden).
Immunohistochemistry
Frozen tissue sections from APP/PS1 mouse brain and AD
cortex were fixed by immersion in 50 % acetone for 1 min
and 100 % acetone for 7 min. The immunohistochemistry
(IHC) procedure was carried out on an automated stainer
(Ventana Discovery XT staining module; Ventana, Illkirch,
France) using Ventana kits and the ‘no pretreatment’ proto-
col prescribed by the manufacturer. A mix of two different
primary antibodies, 4 G8 detecting amyloid-β(27-24) and
6E10 amyloid-β(1-16) (both Signet, Dedham, MA), was
manually applied at a dilution of 1:1,000 (1 μg/ml) for
detection of total plaque load. For detection of tau patholo-
gy, paraffin-embedded paraformaldehyde-fixed (4 %) tissue
and a primary anti-human PHF-tau antibody, AT-8 (Innoge-
netics, Gent, Belgium), at 1 μg/ml were used together with
the standard Ventana CCI protocol. A Ventana Omni-
ultramap kit was used for detection. Finally, the slides were
counterstained with haematoxylin and analysed under the
light microscope.
Statistical analysis and software
Data were analysed using GraphPad Prism 4.03 (GraphPad
Software, San Diego, CA) or the Excel (Microsoft) based
program XL-fit. The results are presented as averages ±
SEM (standard error of the mean). Means of Kd, Bmax,
IC50 were compared using the t-test. Differences were
considered significant at p < 0.05.
Radiochemistry
[3H]AZD2995 was synthesized by N-alkylation of 5-(6-
methoxy-1,3-benzoxazol-2-yl)pyridin-2-amine with [3H]
methyl iodide in dimethylformamide as solvent and sodium
hydride as base as described elsewhere [17]. After purifica-
tion on a C8 reversed-phase HPLC column (60 % v/v
acetonitrile/50 mM ammonium acetate), and subsequent
evaporation of eluent, the purified intermediate [3H-N-meth-
yl]5-(6-methoxy-1,3-benzoxazol-2-yl)-N-methylpyridin-2-
amine was dissolved in N-methyl-2-pyrrolidone. Demethy-
lation was accomplished by adding sodium thiophenoxide
and heating the reaction mixture with microwaves at 250 °C
for 30 min. The reaction mixture was purified on a C8
reversed-phase HPLC column (30 % v/v acetonitrile/50 mM
ammonium acetate) to yield [3H]AZD2995 with an overall
yield of 24 % and a specific activity of 2.5 TBq/mmol. The
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radioactive purity was >98 %. The synthesis of [3H]AZD2814
has been described in detail previously [13, 17]. The specific
activity of [3H]AZD2184 was 2.9 TBq/mmol with a radioac-
tive purity of >98 %. [3H]PIB (2.9 TBq/mmol, radiochemical
purity >99 %) was prepared as described previously [5]. [3H]
AZD2995, [3H]AZD2184 and [3H]PIB were stored in abso-
lute ethanol at −18 °C, at radioactivity concentrations of
typically 37 MBq/ml.
[11C]AZD2184 and [11C]AZD2995 were synthesized as
described in detail elsewhere [12]. After synthesis, the PET
ligands [11C]AZD2184 and [11C]AZD2995 were dissolved
in a solution of sterile disodium phosphate-buffered saline,
pH 7.4, and filtered through a sterile Millipore filter, for
direct administration to the subjects.
PET in human subjects
Subjects and study design
Six control subjects and seven patients with mild to moder-
ate AD were included in the study. The focus of the study
was to evaluate two novel amyloid-β PET radioligands and
not to compare age-matched healthy controls and AD
patients. Therefore younger control subjects were recruited
to ensure no or negligible amyloid-β load in whom the
amount of nonspecific binding could be truly evaluated.
The control subjects were considered healthy, with no symp-
toms of dementia or other neurological disease, after a
neuropsychiatric and somatic examination.
All AD patients were recruited from the Memory Clinic,
Department of Geriatrics, Karolinska University Hospital
Huddinge, Sweden. AD was diagnosed by an experienced
geriatrician according to the DSM-IV criteria including a
Mini-Mental State Examination (MMSE) score [20] be-
tween 16 and 26, brain imaging (MRI or CT) and analysis
of biomarkers in cerebrospinal fluid. The study was ap-
proved by the Regional Ethics Committee in Stockholm,
and was performed in accordance with the Declaration of
Helsinki and the International Conference on Harmoniza-
tion/Good Clinical Practice guidelines. All subjects and
caregivers gave written informed consent before enrolment
in the study.
All six control subjects and seven AD patients underwent
two PET examinations one after intravenous injection of
[11C]AZD2995 and the other after injection of [11C]
AZD2184. Four of the AD patients underwent a second
PET measurement with [11C]AZD2995 as a preliminary
investigation of test–retest variability. [11C]AZD2995 was
injected as a bolus with a mean ± standard deviation, SD)
radioactivity of 410 ± 18 MBq and a specific radioactivity of
620 ± 486 GBq/μmol. [11C]AZD2184 was injected as a
bolus with a radioactivity of 399 ± 43 MBq and a specific
radioactivity of 486 ± 227 GBq/μmol. There were no
significant differences in injected radioactivity or specific
radioactivity between the AD patients and the control sub-
jects for either [11C]AZD2995 or [11C]AZD2184 (p > 0.05).
MRI and PET experimental procedure
All subjects underwent MRI performed on a 1.5-T GE
Medical Systems Signa Excite system at Karolinska Uni-
versity Hospital, Solna. T1-weighted MR images were
obtained and used for segmentation of the grey and white
matter and for delineation of ROIs. The 3-D MR dataset was
reoriented so that the line between the anterior and posterior
commissure was in the horizontal plane and the interhemi-
spheric fissure in the sagittal plane. MR images were seg-
mented into grey and white matter and cerebrospinal fluid
using the SPM5 segmentation algorithm in MATLAB
(Wellcome Trust Centre for Neuroimaging, London, UK;
The Mathworks, Natick, MA).
PET data were obtained on a Siemens/CTI high-
resolution research tomograph operating in list mode [21].
[11C]AZD2995 and [11C]AZD2184 data were acquired for
93 min and 63 min, respectively, after injection. The list-
mode data were binned and reconstructed using iterative
reconstruction with point-spread function modelling into a
4-D PET image dataset. For [11C]AZD2995, the dataset
contained 38 consecutive time frames (9 × 10 s, 2 × 15 s,
3 × 20 s, 4 × 30 s, 4 × 60 s, 4 × 180 s and 12 × 360 s) with a
3-D array of 256 × 256 × 207 voxels with a size of
1.22 × 1.22 × 1.22 mm [21]. For [11C]AZD2184 the image
contained 33 consecutive time frames (9 × 10 s, 2 × 15 s,
3 × 20 s, 4 × 30 s, 4 × 60 s, 4 × 180 s and 7 × 360 s).
Metabolite-corrected arterial input function
The initial part of the arterial plasma input function was
derived using an automated blood sampling system during
the first 5 min [22]. Discrete samples of about 2.2 ml were
then drawn manually at scheduled time points throughout
the PET examination (1, 2, 3, 4, 5, 6.5, 7.5, 8.5, 10.5, 13.5,
16.5, 19.5, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84 and
90 min) for measurement of whole-blood and plasma radio-
activity concentration. The metabolite analyses were per-
formed using standard methodology as described
previously [23], with some minor modifications as de-
scribed here. Venipuncture (or indwelling catheter) samples
of 2.2 ml were collected at fixed time points (4, 10, 20, 30,
40 and 50 min) after radioligand injection. Blood samples
were collected into spray-dried K+ EDTA tubes and radio-
activity was measured in a well counter. Plasma (0.5 ml)
was obtained by centrifugation at 2,000 g for 1 min. Radio-
activity was measured in a well counter, and the plasma was
subsequently mixed with 0.7 ml acetonitrile to precipitate
plasma proteins. The supernatant (1 ml) obtained after
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centrifugation at 2,000 g for 1 min was diluted with 1 ml
water and the mixture was subsequently analysed using
reversed-phase liquid chromatography (Waters μBondapak
C18 column 7.8 × 300 mm, 10 μm, with acetonitrile/0.1 M
ammonium formate as mobile phase and a flow rate of 6 ml/
min). [11C]AZD2995 was analysed using a mobile phase
gradient of 40 % to 55 % acetonitrile over 12 min and then a
wash-out phase using 80 % acetonitrile.
Regions of interest
Anatomical ROIs were manually delineated on the reoriented
1 × 1 × 1-mm resolution MR images using the Human Brain
Atlas [24]. ROIs were delineated as previously defined [25],
and included the following regions: anterior cingulate cortex,
hippocampus, lateral temporal cortex, parietal cortex, posteri-
or cingulate cortex, prefrontal cortex, pons and putamen. The
cerebellum was used as reference region and delineated to
include the cortex but avoiding white matter and the vermis.
Segmented images of total greymatter white matter and whole
brain were created during image processing as described
above and used to create the respective ROIs. The segmented
grey matter was also used in ROI extraction to only include
grey matter voxels in the manually delineated cortical ROIs
described above.
Quantitative analysis
[11C]AZD2995 binding was quantified using the linear
graphical method proposed by Logan et al. [26]. Using the
metabolite-corrected arterial blood curve as input function,
six points in the linear part of the Logan plot were fitted to
obtain the total distribution volume (VT) for [
11C]AZD2995
(13 to 45 min after injection). In addition, both [11C]
AZD2995 and [11C]AZD2184 were evaluated with the ref-
erence Logan (refLogan) method using the cerebellum as
the reference region. The cerebellum was chosen since it is
known to be devoid of substantial amounts of fibrillar
amyloid-β [27, 28], and has previously been successfully
used as a reference region [14, 29–31]. To obtain the VT, the
Fig. 1 Saturation binding (a)
and Scatchard plot (insert)
showing two distinct binding
sites on synthetic Aβ(1-40)
fibrils. The high-affinity site
(Kd 6.2±0.6 nM) appears at a
lower density (Bmax 0.8±0.1
pmol/nmol) than the low-
affinity site (Kd 73.4±7.5 nM;
Bmax 4.3±0.3 pmol/nmol). b
The IC50 values for AZD2995
increased linearly with increas-
ing [3H]PIB concentrations,
demonstrating that AZD2995
and PIB bind to the same site in
a competitive manner
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same number of frames (six) were used in the linear part of
the curve for [11C]AZD2995 (13 to 45 min after injection)
and [11C]AZD2184 (30 to 60 min). Due to the fast washout
of [11C]AZD2995 the low radioactivity in the later part of
PET data acquisition resulted in a positive bias due to poor
counting statistics. Therefore earlier time frames were used
for quantification using the Logan method for [11C]
AZD2995 than for [11C]AZD2184.
The distribution volume ratio (DVR) was calculated as
the ratio between VT in the target region divided by that in
the reference region, i.e. the cerebellum. Detailed informa-
tion regarding quantification is planned to be presented
elsewhere.
Parametric images for visualization were produced using
reference wavelet-aided parametric imaging (refWapi) for
noise reduction and parametric calculation performed using
the refLogan method in a similar manner to the ROI-based
analysis [32]. The outcome measure was the binding poten-
tial (BP) calculated as DVR − 1, DVR estimated using the
refLogan method performed within refWapi [32].
Statistical analysis and software
Group differences in demographic parameters were analysed
inWindows Excel and calculated using a two-tailed t-test with
unequal variance. Test–retest variability was calculated for
each region as the absolute value of the difference between
test and retest values divided by the mean of the two measure-
ments. Test–retest variability is reported for selected ROIs as
means ± SD across all test–retest subjects in units of percent-
age. The intraclass correlation coefficients were calculated to
characterize measurement reliability [33]. The intraclass cor-
relation coefficient estimates how much of the total variance
of the test–retest dataset originates from the measurement
error (within-subject variance) in proportion to the intersubject
variance (range −1 to 1). Group differences in binding param-
eters for the corresponding radioligand were calculated using
PASW Statistics 18 with independent-samples Mann–Whit-
ney U test, and were considered significant at p < 0.05. The
standardized differences in the group mean estimates between
AD patients and control subjects were also calculated. Stan-




Binding to amyloid-β fibrils in vitro
Saturation binding studies in vitro with up to 130 nM of [3H]
AZD2995 revealed two distinct binding sites on synthetic
Aβ(1-40) fibrils as demonstrated by both Scatchard plot anal-
ysis (Fig. 1a) and nonlinear regression analysis. The high-
affinity site (Kd 6.2±0.6 nM) appears at a lower density (Bmax
0.8±0.1 pmol/nmol) than the low-affinity site (Kd 73.4±7.5
nM; Bmax 4.3±0.3 pmol/nmol).
The binding of AZD2995 to amyloid-β fibrils was ex-
amined in a competition binding assay in which the dis-
placement of the reference radioligand [3H]PIB from Aβ(1-
40) amyloid fibrils was measured at three different concen-
trations of [3H]PIB (Fig. 1b). AZD2995 bound with high
affinity to Aβ(1-40) and was able to successfully displace
[3H]PIB binding (Fig. 1b). The pIC50 values of AZD2995
increased in a linear fashion with increasing concentrations
of [3H]PIB, supporting a competitive interaction between
the ligands. The binding of [3H] AZD2995 was reversible
with a two-phase dissociation with half-lives (T1/2) of
0.2 ± 0.04 min and 8.9 ± 1.2 min. AZD2995 inhibited
[3H]PIB (3 nM) binding to synthetic Aβ(1-40) amyloid
fibrils with a similar affinity as to Aβ(1-42) amyloid fibrils
(pIC50 6.77 ± 0.02; IC50 170.42 nM, pIC50 6.69 ± 0.05; IC50
203.77 nM, respectively).
Fig. 2 PET ligand nonspecific binding is correlated well with elogD
(a), in contrast to ligand affinity towards amyloid which is not corre-
lated with elogD (b). Nonspecific binding was determined using auto-
radiography of the binding of the tritiated ligands to white matter in
human brain slices
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Nonspecific binding was defined from the autoradio-
grams of tritiated labelled ligand binding to white mat-
ter in human AD brain slices. The analyses comparing
reported effective logD (elogD) values [17] with the
measured degree of nonspecific binding and amyloid-β
fibril affinity revealed that nonspecific binding was cor-
related with eLogD (Fig. 2a). However, no correlation
was found between amyloid-β PET ligand affinity and
ligand eLogD (Fig. 2b).
In vitro autoradiography and immunohistochemistry
In vitro binding studies were performed on sections of
whole brain from APP/PS1 transgenic mice and dissected
cortical tissue sections from AD patients. [3H]AZD2995
selectively labelled amyloid-β plaques in brain sections
from APP/PS1 mice and most abundantly in the cortex
and hippocampus (data not shown). In vitro binding studies
of [3H]PIB, [3H]AZD2184 and [3H]AZD2995 on cortical
tissue from AD patients demonstrated binding to amyloid-β
deposits in a similar manner (Fig. 3). [3H]AZD2995 and
[3H]AZD2184 binding was most abundant in superficial
layers of the cortex (grey matter) and more sparse in fibre
tracts and in subcortical white matter (Fig. 3). Analysis of
amyloid-β binding in post mortem human brain tissue sec-
tions, demonstrated that at a radioligand concentration of
3 nmol/l, the ratio between grey matter binding (specific)
and white matter binding (nonspecific) was higher for [3H]
AZD2995 than for [3H]PIB and [3H]AZD2184 (Fig. 3).
The binding of [3H]AZD2995 and [3H]AZD2184 was
examined by comparing autoradiography results with IHC
using anti-Aβ selective antibodies in human AD cortical
tissue. Microscopic analysis of 7-μm sections of AD brain
revealed that the [3H]AZD2995 and [3H]AZD2184 labelling
matched the IHC labelling of Aβ (Fig. 4a–c). High-
resolution autoradiography revealed selective binding of
[3H]AZD2995 and [3H]AZD2184 to dense core amyloid-β
plaques as well as diffuse amyloid-β plaques (Fig. 4a–c).
To explore the selectivity of [3H]AZD2995 and [3H]
AZD2184 binding to Aβ-fibrils compared to tau deposits
(tangles), high-resolution autoradiography of [3H]AZD2995
and [3H]AZD2184 compared to total Aβ IHC (6E10/4 G8)
and PHF-tau IHC (AT8) was performed on thin (4-μm)
paraffin-embedded adjacent tissue sections. No correlation
between tau pathology and [3H]AZD2995 or [3H]AZD2184
binding was observed at 1 nM (Fig. 4d).
PET in human subjects
Before entering human PET studies [11C]AZD2995 was in-
vestigated in nonhuman primates to ensure sufficient brain
exposure. In nonhuman primates [11C]AZD2995 rapidly en-
tered the brain with an exposure of about 1 % of total injected
radioactivity (Supplementary Fig. 1). This observation sup-
ported further examination in human subjects. The study was
performed according to “The guidelines for planning, conduc-
tion, and documenting experimental research” (Dnr 4820/06-
600) of Karolinska Institutet as well as the guidelines in
Fig. 3 Autoradiograms of tissue
sections from human AD brain
incubated with 3 nM of (a) [3H]
PIB, (b) [3H]AZD2184 and (c)
[3H]AZD2995. Quantification of
the signal-to-noise ratios of the
three ligands is presented in the
bar graph below
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Principles of Laboratory Animal Care (NIH publication no.
85-23, revised 1985). The study was approved by the Animal
Ethics Committee of the Swedish Animal Welfare Agency
and was consistent with applicable regulatory requirements
and the AstraZeneca policy on Bioethics.
Subjects
Six control subjects (all men) and seven AD patients (six
men, one woman) underwent PET examination. Due to
technical issues related to data acquisition and storage, data
from three control subjects examined in the same week were
not usable. The age range of the three remaining control
subjects was 24–36 years and the age (mean ± SD) of the
AD patients was 68 ± 11 years (range 56 to 81 years). The
MMSE score (mean ± SD) was 22 ± 3 in AD patients.
Arterial input function and radioligand metabolism
Blood samples were taken during the [11C]AZD2995 PET
examination. Time curves for radioactivity in whole blood
and metabolite-corrected plasma were similar across control
subjects and AD patients (Fig. 5a). The metabolism of [11C]
AZD2995 was very rapid in both AD patients and control
subjects. About 50 % of the radioligand was metabolized
within 5 min of injection (Fig. 5b). The radioactive metab-
olites produced were more polar than the parent compound
(Fig. 5c).
Time–activity curves
After intravenous injection of [11C]AZD2995 the time–ac-
tivity curves for total radioactivity in brain increased rapidly
reaching a peak after about 1 min when 2.5–3.5 % of
radioactivity was in the brain (Fig. 6a). By comparison,
the peak for [11C]AZD2184 was reached at the same time
as 3.0–3.5 % of radioactivity was seen in the brain (Fig. 6b).
Representative time–activity curves for [11C]AZD2995 and
[11C]AZD2184 in a control subject and an AD patient are
presented in Fig. 7. For both radioligands there was a rapid
decline in radioactivity after the initial peak, although the
washout was faster for [11C]AZD2995 than for [11C]
AZD2184. In AD patients, radioactivity was higher in cor-
tical areas than in the white matter and cerebellum for both
radioligands. In the white matter, the radioactivity after
injection of [11C]AZD2995 was lower than after injection
of [11C]AZD2184. In control subjects, [11C]AZD2995 bind-
ing was equal in the grey matter, white matter and cerebel-
lum, while [11C]AZD2184 binding was somewhat higher in
the whiter matter.
Quantification
Full kinetic modelling for [11C]AZD2995 and [11C]AZD2184
will be presented elsewhere. Data for [11C]AZD2995 was
successfully fitted using the Logan plot with metabolite-
corrected arterial input function. The simplified refLogan
approach described the data for both [11C]AZD2995 and
[11C]AZD2184. Parametric images of BPs for [11C]
AZD2995 and [11C]AZD2184 overlaid on respective MR
images are presented for representative individuals in Fig. 8.
The individual DVRs in the grey matter of control subjects
and AD patients are given in Fig. 9. The DVRs estimated for
[11C]AZD2995 using the refLogan method were consistent
with the DVRs estimated with the Logan method using a
Fig. 4 High-resolution autoradiography imaging of (a) 3nM [3H]
AZD2995 and (b) 3 nM [3H]AZD2184 compared to IHC of (c) total
amyloid-β plaque load (6E10/4G8) and (d) tau pathology (AT-8) in
tissue sections from the same AD post mortem brain sample
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metabolite-corrected input curve (Supplementary Fig. 2). In
all AD patients, the DVRs of the grey matter were lower for
[11C]AZD2995 than for [11C]AZD2184.
General observations of regional binding
In control subjects, nonspecific binding was low and homo-
geneous for both radioligands, and was lower for [11C]
AZD2995 (Fig. 8). Specific binding was demonstrated for
both radioligands in cortical regions known to have high
amounts of amyloid-β plaques including the frontal, parietal
and posterior cingulate cortices. In AD patients, the BP values
were lower for [11C]AZD2995 than for [11C]AZD2184.
Group differences
The mean DVRs estimated with the refLogan method for
[11C]AZD2995 and [11C]AZD2184 are given in Table 1.
DVR values for the two radioligands significantly separated
control subjects and AD patients (Table 1). The effect sizes
were generally smaller for [11C]AZD2995 than for [11C]
AZD2184, except for two regions (the lateral temporal
Fig. 5 a Group-wise interindi-
vidual mean radioactivity con-
centrations of [11C]AZD2995 in
arterial whole blood and
metabolite-corrected plasma in
AD patients (AD, n=6) and
control subjects (HC, n=3). b
Parent fraction of [11C]
AZD2995 in relation to time in
arterial plasma. c Chromato-
gram showing radioactive par-
ent and metabolites of [11C]
AZD2995 at four time points
after injection
Fig. 6 Percent injected activity
(means ± SD) in relation to time
for (a) [11C]AZD2995 and (b)
[11C]AZD2184 in AD patients
(AD) and control subjects (CS)
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Fig. 7 Representative time–
activity curves for [11C]
AZD2995 and [11C]AZD2184
in an AD patient (a, b) and a
control subject (c, d) (GM grey
matter, WM white matter, CER
cerebellum)
Fig. 8 Parametric images of BPs for [11C]AZD2995 and [11C]AZD2184 overlaid on respective MR images in control subject S124 and AD patient S101
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cortex and hippocampus) in which the effect sizes were
larger for [11C]AZD2995 than for [11C]AZD2184.
Test–retest variability
Four AD patients (AD4, AD5, AD6 and AD7) underwent a
second PET scan with [11C]AZD2995 to estimate the test–retest
variability of the radioligand. Regional DVRs estimated using
the refLogan method had a test–retest variability ranging from
1.4% to 4.3% in the greymatter (Table 2). Intraclass correlation
coefficients were generally large, ranging from 0.77 to 0.99.
Discussion
Imaging methodology for accurate measurements of low
amounts of amyloid-βwould serve as a valuable research tool
when studying individuals with AD at a preclinical stage, or
when disease progression in relation to disease-modifying
treatment is to be followed longitudinally [34]. The currently
most widely used amyloid-β radioligand, [11C]PIB, has rela-
tively high nonspecific binding to white matter, which may
limit its ability to detect small changes [35]. In the present
study, we examined the in vitro and in vivo binding properties
of the more recently developed radioligand [11C]AZD2995.
This radioligand has low lipophilicity when compared with
previously developed radioligands, and the aim was to deter-
mine if this physicochemical property translates into advan-
tages for detection of low amounts of amyloid-β.
Binding characteristics
The specificity of AZD2995 binding to amyloid-β was
confirmed using binding and competition assays. As is seen
with other amyloid-β ligands, one high-affinity and one
low-affinity binding site were identified [6, 13]. However,
the low-affinity binding site will not significantly contribute
to the specific binding component since the radioligands are
used in low nanomolar concentrations in PET imaging.
The in vitro binding of [3H]AZD2995 in APP/PS1 trans-
genic mice and AD post mortem tissue was comparable to
that of [3H]AZD2184, being most abundant in areas known
to contain large amounts of amyloid-β plaques, including
the frontal cortex as shown in the present study, and was
distributed in the cortical layers in a pattern similar to that of
[3H]PIB [5, 6]. Brain tissue from an ApoE 4/4 carrier was
for autoradiography and IHC, and this AD patient was not
representative of all AD patients but was appropriate given
the aim to compare the binding properties and signal-to-
background ratio between the different ligands. Although all
three amyloid-β ligands examined in these experiments
display a high level of correspondence in their regional
Fig. 9 Individual DVR) values in control subjects (IDs 124–126) and
AD patients (IDs 101–107) using [11C]AZD2995 and [11C]AZD2184,
respectively



















[11C]AZD2995 DVR (mean ± SD)
AD patients 1.03 ± 0.06 1.47 ± 0.11 1.46 ± 0.14 1.63 ± 0.14 1.68 ± 0.20 1.80 ± 0.18 1.64 ± 0.19 1.20 ± 0.07
Control subjects 0.75 ± 0.17 1.01 ± 0.05 0.80 ± 0.09 1.01 ± 0.06 0.94 ± 0.08 1.12 ± 0.10 0.94 ± 0.11 1.04 ± 0.04
Effect size 3.35 5.13 5.44 5.37 4.55 4.49 4.37 2.78
p valuea 0.017 0.017 0.017 0.017 0.017 0.017 0.017 0.017
[11C]AZD2184 DVR (mean ± SD)
AD patients 1.25 ± 0.05 1.72 ± 0.17 1.97 ± 0.15 1.94 ± 0.22 2.07 ± 0.25 2.10 ± 0.18 2.13 ± 0.23 1.11 ± 0.10
Control subjects 1.08 ± 0.13 1.05 ± 0.05 0.92 ± 0.02 1.03 ± 0.05 1.04 ± 0.04 1.17 ± 0.02 1.04 ± 0.04 0.95 ± 0.08
Effect size 2.67 4.89 8.52 5.00 5.26 6.34 5.82 1.73
p valuea 0.030 0.017 0.017 0.017 0.017 0.017 0.017 0.030
a Significant at p < 0.05, calculated using independent-samples Mann–Whitney U test.
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selectivity patterns, there were differences regarding the
contrast between specific and nonspecific binding (Fig. 3).
[3H]AZD2184 demonstrated the highest signal in cortical
tissue, but nonspecific binding in the white matter was
lowest for [3H]AZD2995. Since AZD2995 has a slightly
lower affinity (Kd 6.2 nM) than AZD2184 (Kd 4.9 nM) and
PIB (Kd 4.8 nM), this low nonspecific binding may be a
major reason for the higher signal-to-background ratio for
[3H]AZD2995 than for [3H]AZD2184 and [3H]PIB [13].
Interestingly, the difference in nonspecific binding and
background followed the rank order of lipophilicity between
the radioligands, with [3H]AZD2995 having the lowest lip-
ophilicity and background, [3H]AZD2184 intermediate and
[3H]PIB the highest (Fig. 3). This is in line with what was
predicted by the results showing a correlation between lip-
ophilicity and amount of nonspecific binding (Fig. 2a).
The specificity of [3H]AZD2995 binding to amyloid-β
was further evaluated by high-resolution imaging of incu-
bated emulsion-dipped tissue sections that were compared
with adjacent sections stained for amyloid-β or tau by IHC.
[3H]AZD2995 selectively labelled both diffuse plaques and
dense core plaques in a similar manner to [3H]PIB [36], [3H]
AZD2184 [13] and [3H]AZD4694 [15], while only core
plaques were labelled in transgenic mice (Fig. 4). Further-
more, [3H]AZD2995 did not bind tau deposits at low con-
centrations. Binding to tau will therefore not have an impact
on a signal seen with PET using nanomolar concentrations
of radioligand.
Initial preclinical characterization suggests that [11C]
AZD2184 has the most promising properties for group sepa-
ration with a higher binding affinity and a strong signal, but
radiolabelled AZD2995 might be a more sensitive tool for
imaging low levels of amyloid-β in vitro as well as in vivo.
In vivo binding in human subjects
[11C]AZD2995 showed a very low and homogeneously
distributed nonspecific binding in control subjects similar
to the pattern that has been previously reported for [11C]
AZD2184 [14]. There were no obvious differences in re-
gional brain distribution of radioactivity in control subjects
after injection of [11C]AZD2995 and [11C]AZD2184, al-
though the latter showed somewhat higher DVR values in
most regions. In control subjects, [11C]AZD2995 entered
the brain rapidly and the brain exposure was slightly lower
than that for [11C]AZD2184 [14]. The lower exposure for
[11C]AZD2995 might have been due to the lower nonspe-
cific binding as shown in the preclinical analyses. One
limitation of this study was the low number of control
subjects due to technical issues in three PET examinations.
It is also worth noting that the study was designed to
compare the specific binding in AD patients of the two
novel amyloid PET radioligands with that in controls devoid
of specific binding. This was the reason for inclusion of
young healthy controls rather than age-matched control
subjects. Further studies are needed to evaluate the sensitiv-
ity and specificity of these radioligands in larger age-
matched samples.
In AD patients, [11C]AZD2995 as well as [11C]AZD2184
displayed reversible binding and rapid washout. All labelled
metabolites of [11C]AZD2995 detected were more polar
than the parent as estimated from the elution order on
reversed-phase HPLC, which should make them less likely
to pass the blood–brain barrier. These observations promp-
ted an initial quantitative analysis using standard quantifi-
cation methods such as the Logan plot. The regional
distribution of [11C]AZD2995 radioactivity in AD patients
was similar to that found for other amyloid-β radioligands
showing high binding in the parietal, frontal, parietotempo-
ral and posterior cingulate cortices [5, 14, 30]. This obser-
vation further supports the preclinical observations of
specific binding to amyloid-β plaques.
[11C]AZD2995 showed significant differences in binding
between AD patients and healthy controls, although it had a
lower effect size than [11C]AZD2184. [11C]AZD2184 may
therefore be favoured for further studies aiming at investi-
gating amyloid-β pathology in relation to functional
changes and separating subjects with and without amyloid-
β pathology. Nevertheless, [11C]AZD2995 showed a greater
effect size than [11C]AZD2184 in the hippocampus and the
lateral temporal cortex, supporting the notion that this radio-
ligand might be useful for studying areas with small incre-
ments in amyloid-β pathology, taking advantage of the low
background binding. [18F]FDDNP has so far been the only
amyloid ligand for which it has been possible to relate
pathological progression and cognitive decline [10, 37],
although these findings were not replicated in a study show-
ing no relationship between increased levels of FDDNP and
progression from mild cognitive impairment to AD. Recent
large studies using [11C]PIB have begun to show patterns


















Test–retest variability (%) 1.9 ± 1.3 1.1 ± 0.8 4.3 ± 3.0 2.1 ± 0.9 4.2 ± 2.4 1.4 ± 1.0 3.0 ± 1.8 3.9 ± 1.9
Intraclass correlation coefficient 0.90 0.99 0.77 0.97 0.97 0.97 0.98 0.88
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between amyloid deposition and early cognitive changes
[38] as well as a markedly greater conversion rate in [11C]
PIB-positive patients with mild cognitive impairment than
in [11C]PIB-negative patients [39].
Applications
AZD2995 and AZD2184 were developed as amyloid-β
ligands with less lipophilicity than PIB in order to achieve
improved specific to nonspecific binding ratios. This phys-
icochemical property is the most likely explanation for the
improved specific/nonspecific ratio demonstrated in vitro
using autoradiography (Fig. 3). This is an advantage in
preclinical studies in which higher concentrations are used
than for PET in humans. For example, in the present in vitro
study concentrations in the range 1–3 nM were used, which
are about 60 times higher than the concentration used in
PET studies. It should be mentioned that a drawback with
11C ligands compared to 18F ligands is that the positron
range of the former is somewhat larger, and this will have
a small impact on the resolution. Although the low back-
ground binding observed with [11C]AZD2995 could also be
important in translational studies using micro-PET in which
the injected dose is usually about 20–60 times higher than
for PET in humans. The use of a radioligand with very low
nonspecific binding could also be an advantage in micro-
PET due to the expected larger partial volume effect caused
by the very small size of the brain in relation to the resolu-
tion of the PET system.
A lot of interest has been shown in the development of
18F-labelled amyloid-β radioligands due their longer half-
life. Nevertheless, 11C-labelled radioligands are advanta-
geous in multitracer protocols making it possible to study
both amyloid-β load as well as inflammation, receptor lev-
els and glucose metabolism, to mention a few options. Both
radioligands showed properties indicating their potential
value as research tools. [11C]AZD2995 showed better sepa-
ration in regions such as the hippocampus which are known
to have lower amyloid-β pathology but are still involved in
functional deterioration, and [11C]AZD2184 showed higher
specific binding and good separation between AD patients
and control subjects. The potential usefulness of [11C]
AZD2995 in translational and clinical research is further
supported by the low test–retest variability, even lower than
that shown by [11C]PIB [29, 40].
Conclusion
[11C]AZD2995 as well as [11C]AZD2184 have low lipophi-
licity which results in very low nonspecific binding and high
signal-to-background ratio in AD brain tissue. The low
nonspecific binding was further established in PET in
humans which highlighted the ability of [11C]AZD2995 to
depict amyloid-β pathology in areas with only a slight
increase. In small-animal PET the high contrast seen with
[11C]AZD2995 could be of importance in allowing the
study of small brain structures. [11C]AZD2995 could there-
fore be a valuable tool in studies focusing on early prodro-
mal stages of AD, in longitudinal studies, or in micro-PET.
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